Our top pick for
Quidel Corporation is a diagnostics & research business based in the US. Quidel Corporation shares (QDEL) are listed on the NASDAQ and all prices are listed in US Dollars. Quidel Corporation employs 1,250 staff and has a trailing 12-month revenue of around USD$1 billion.
|Latest market close||USD$189.97|
|52-week range||USD$68.66 - USD$306.72|
|50-day moving average||USD$228.2183|
|200-day moving average||USD$218.133|
|Wall St. target price||USD$285.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$8.537|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-2.55%|
|1 month (2020-12-15)||-5.42%|
|3 months (2020-10-15)||-28.61%|
|6 months (2020-07-15)||-22.83%|
|1 year (2020-01-15)||145.53%|
|2 years (2019-01-15)||256.22%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-15)||973.28%|
Valuing Quidel Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Quidel Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Quidel Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Quidel Corporation shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Quidel Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 7.19. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Quidel Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Quidel Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$537.4 million.
The EBITDA is a measure of a Quidel Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1 billion|
|Operating margin TTM||48.41%|
|Gross profit TTM||USD$320.8 million|
|Return on assets TTM||28.72%|
|Return on equity TTM||53.6%|
|Market capitalisation||USD$8.4 billion|
TTM: trailing 12 months
There are currently 2.5 million Quidel Corporation shares held short by investors – that's known as Quidel Corporation's "short interest". This figure is 3% up from 2.4 million last month.
There are a few different ways that this level of interest in shorting Quidel Corporation shares can be evaluated.
Quidel Corporation's "short interest ratio" (SIR) is the quantity of Quidel Corporation shares currently shorted divided by the average quantity of Quidel Corporation shares traded daily (recently around 946523.01886792). Quidel Corporation's SIR currently stands at 2.65. In other words for every 100,000 Quidel Corporation shares traded daily on the market, roughly 2650 shares are currently held short.
However Quidel Corporation's short interest can also be evaluated against the total number of Quidel Corporation shares, or, against the total number of tradable Quidel Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Quidel Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Quidel Corporation shares in existence, roughly 60 shares are currently held short) or 0.0974% of the tradable shares (for every 100,000 tradable Quidel Corporation shares, roughly 97 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Quidel Corporation.
Find out more about how you can short Quidel Corporation stock.
We're not expecting Quidel Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Quidel Corporation's shares have ranged in value from as little as $68.66 up to $306.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Quidel Corporation's is 0.495. This would suggest that Quidel Corporation's shares are less volatile than average (for this exchange).
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.